FRAGMENT SCREENING IN LEAD DISCOVERY BY WEAK AFFINITY CHROMATOGRAPHY (WAC )
|
|
- Marlene Osborne
- 5 years ago
- Views:
Transcription
1 FRAGMENT SCREENING IN LEAD DISCOVERY BY WEAK AFFINITY CHROMATOGRAPHY (WAC ) SARomics Biostructures AB & Red Glead Discovery AB Medicon Village, Lund, Sweden
2 Fragment-based lead discovery The basic idea: Screen few fragments (100 1,000) - Less complex molecules higher probability to bind - Less resource intensive than HTS - Better sampling of chemical space Find weak but efficient i (high h binding energy per atom) binders Develop into more potent compounds using structural information HTS hit Fragment hits Boyd, Turnbull & Walse (2012) Fragment library design considerations, WIREs Comput. Mol. Sci., 2,
3 Conventional HTS vs. fragment screening in drug discovery Figure adapted from Duong-Thi, 2013, Thesis.
4 Structure-based and fragment-based discovery of vemurafenib Vemurafenib (PLX4032) The usage of FBLD combined with SBDD was a critical success factor in the development of vemurafenib
5 Fragment-based lead discovery Fragment screening Medicinal chemistry Synthesis (small molecules & peptides) Analytical chemistry (NMR & MS/MS) In vitro biology In vitro ADME/physchem HTS/FBLG expertise Screening technologies In silico screening Thermoshift assay (DSF) NMR WAC Biochemical screening (HCS) X-ray crystallography MST Compounds Proprietary library Specifically ordered sets Client libraries Structure-based drug design X-ray crystallography Computational chemistry NMR spectroscopy Biophysics Protein chemistry
6 Primary screening techniques NMR screening Thermal shift assay / DSF Weak Affinity Chromatography Sample changer screens 96 samples overnight Cryoprobe equipped 800 MHz NMR instrument Ligand-observed 1 H NMR spectra NMR analysis/titration of selected hits Initial screening 0.1 mg g/ /ml 0.2 mg/ml ΔTm at 62.5 μm ΔTm at 62.5 μm RG RG RG RG RG RG Dose response curves Target protein immobilized on HPLC column MS-detection Physiological buffer as mobile phase Retention time of fragments related to selective interactions ti with targett Simultaneous identification of weak binders (mm) in complex mixtures
7 Secondary and follow-up techniques X-ray crystallography MST, microscale thermophoresis HCS high concentration biochemical screening High-throughput low volume crystallization Soaking pools of fragments Co-crystallization ti of selected fragments High-throughput data collection (autom. synchrotron beamlines) Structure determination and refinement through automated data pipelines pp EC50=44 µm Versatile plate readers FRET, TRF, AlphaLisa, fluorescence polarization etc Crystallization robotics MAX IV Measures the motion of molecules along microscopic i temperature t gradients K d, dissociation constant: nm to mm range Rapid assay optimization Fast measurement: K d in 10 min Low sample consumption: minimal concentration (nm) and small volume (<4 µl) well plate Development and optimization Buffer composition, Additions, Linearity, Kinetic parameters Screening Robustness (Z -factor), reagent stability, reproducibility (day-to-day variation), DMSO sensitivity, automation
8 Weak affinity chromatography (WAC ) Principles i of WAC Data analysis Affinity constant (KD) is calculated from the retention time difference ( t ret ) for the compounds on target and blank columns. Column with immobilized protein Fragment binding WAC attractive as primary fragment screening assay Column without protein (blank column) Column cross section Invented by Prof. Sten Ohlson (Linnaeus University, it Sweden) Commercial rights by Transientic Interactions AB (TI) SARomics and RGD in unique collaboration with TI offering exclusive service platform Fragment mix Affinity LC-MS column Schematic representation of screening using WAC 0.5 minutes retention time difference is significant Extracted ion chromatograms K D = B tot /( t ret flowrate)
9 Some technical details WAC Typical setup: Target protein coupled via lysine residues Mixes of cmpds (1 µm, n=2) ~1-4 mg protein on LC column (e.g. 2.1 x 50 mm) Each LC run of minutes Affinity range: 100 µm 4 mm (can be adjusted)
10 WAC data on bromodomain (BRD4) Application within Nile project
11 BRIEF SUMMARY WAC-screening of 155 fragments Fragment lib. MW: , average MW = fragment-mixtures 20 mm sodium acetate buffer Robustness Unchanged performance of BRD4-column over time (>1 months at least) Re-test with every two 10-mixes pooled into one 20-mix provided very similar results RG (IC50 = 40 µm in biochemical assay) included in all mixes as control; ( µ y) ; Retention time = 138 ± 5 minutes (%CV = 3.9%) on BRD4-column (n=18)
12 Actives Retention time difference was used to identify actives: Δt ret = t BRD4-col t control_column A fragment with Δt ret > 2 minutes considered to active (provided that also (Δt ret /t BRD4-col ) > 0.1) Data suggest that t WAC has a lower degree of false positives than other techniques such as DSF and high h concentration biochemical screening No screened 155 No hits (Δt ret > 2 min) 23 No strong hits (Δt ret > 5 min) 13 Hit rate 15% WAC only technique revealing RG reported by Pfizer as BRD4 binding fragment Ref: Fish et al., J Med Chem (2012), 55(22), 9831 H N RG O Br N
13 Comparison with other techniques BRD4 screening hits HSP90 screening hits Using a WAC -cutoff of t ret > 5 min, all fragments verified by other Screening of 111 fragments by WAC, techniques except: NMR, SPR, FP and Tm shift. Selected RG and RG (reference cmpd Pfizer-hit ) fragments also by ITC and X-ray RG and RG not tested in other assays crystallography. Fragments listed with decreasing affinities as measured by WAC. (Meiby et al. 2013, Anal. Chem., Compound ID Δt ret (min) WAC Biochem DSF NMR X-ray 85, 6756) RG A (IC50 ~50 µm) A NT YES RG A (56%@100µM) A NT YES RG Tendency of activity A NT YES RG A (54%@100µM) A NT YES RG Tendency of activity A NT YES RG A (45% inhib@100µm) A NT YES RG A (31% inhib@100µm) A NT YES RG NA NA NA 4HBV RG NA A NA NT RG NT NA A NT RG NA NA NT NT RG NT NT A NT RG Not tested in any other assay RG Not tested in any other assay A = active; NA = not active; NT = not tested
14 Hit rate BRD PPI 70% 60% 50% 40% 30% 20% 10% 0% 61% 12% < 0.25 min 0.25 to 0.5 min 9% 6% 7% 5% 0.5 to 1 min 1 to 2 min 2-5 min > 5min 100% 90% 80% 70% 60% 50% 40% 30% 20% 10% 0% 86% 8% < 0.25 min 0.25 to 0.5 min 3% 2% 1% 0% 0.5 to 1 min 1 to 2 min 2-5 min > 5min Screens performed in duplicate
15 WAC for complex mixtures Reaction mixtures Extracts from natural sources, i.e. natural products Analysis of Protein Target Interactions of Synthetic y g y Mixtures by Affinity-LC/MS. Singh et al. SLAS Discov Apr;22(4):
16 Beneficial WAC characteristics Throughput mixes, detection of multiple binders Robustness low variation between replicates, long column life time Cost efficiency low consumption of protein and fragments, standard equipment Quality automatic quality control, not sensitive for impurities Ranking immediate ranking
Introduction to FBDD Fragment screening methods and library design
Introduction to FBDD Fragment screening methods and library design Samantha Hughes, PhD Fragments 2013 RSC BMCS Workshop 3 rd March 2013 Copyright 2013 Galapagos NV Why fragment screening methods? Guess
More informationUnlocking the potential of your drug discovery programme
Unlocking the potential of your drug discovery programme Innovative screening The leading fragment screening platform with MicroScale Thermophoresis at its core Domainex expertise High quality results
More informationImplementation of novel tools to facilitate fragment-based drug discovery by NMR:
Implementation of novel tools to facilitate fragment-based drug discovery by NMR: Automated analysis of large sets of ligand-observed NMR binding data and 19 F methods Andreas Lingel Global Discovery Chemistry
More informationMonolith NT.Automated Product Information
Monolith NT.Automated Product Information Monolith Instruments for MicroScale Thermophoresis www.nanotemper-technologies.com Monolith NT.Automated Product Information 2 www.nanotemper-technologies.com
More informationGyörgy M. Keserű H2020 FRAGNET Network Hungarian Academy of Sciences
Fragment based lead discovery - introduction György M. Keserű H2020 FRAGET etwork Hungarian Academy of Sciences www.fragnet.eu Hit discovery from screening Druglike library Fragment library Large molecules
More informationFragment-based drug discovery
Fragment-based drug discovery Dr. Till Kühn VP Applications Development MRS, Bruker BioSpion User s meeting, Brussels, November 2016 Innovation with Integrity The principle of Fragment Based Screening
More informationNMR Solutions for drug discovery
NMR Solutions for drug discovery Dr. Matteo Pennestri London, UK Bruker Users Meeting Innovation with Integrity The principle of Fragment Based Screening from efficient fragments to Drug candidates Fragment
More informationFragment Screening in Drug Discovery
Fragment Screening in Drug Discovery Marc Martinell SEQT, Sitges, 19th-20th October 2006 Crystax Pharmaceuticals SL Barcelona Science Park Josep Samitier 1-5, E-08028 Barcelona Tel: +34 93 403 4703 Fax
More informationFragment-Based Drug Discovery (FBDD) Using the dispr Technique on Pioneer Systems with OneStep and NeXtStep Injection Methodologies
APPLICATION NOTE 21 Fragment-Based Drug Discovery (FBDD) Using the dispr Technique on Pioneer Systems with OneStep and NeXtStep Injection Methodologies Eric L. Reese, Ph.D, SensiQ Technologies, Aaron Martin
More informationBuilding innovative drug discovery alliances
Building innovative drug discovery alliances Hit optimisation o using fragments Mark kwhittaker Evotec AG, Fragments 2015, March 2015 Agenda Fragment optimisation in an ideal world Fragment optimisation
More informationZ -LYTE Assay Setup Guide on the BMG LABTECH CLARIOstar Reader
08 Jan 15 Page 1 of 18 Z -LYTE Assay Setup Guide on the BMG LABTECH CLARIOstar Reader The BMG LABTECH CLARIOstar Microplate Readers were tested for compatibility with the Life Technologies Z -LYTE Assay
More informationSmall-Molecule Kinetics
Application Note No. 1 / September 1, 2014 Small-Molecule Kinetics Creoptix WAVE Small-Molecule Kinetics: Binding of Sulfonamides to Carbonic Anhydrase II Summary Label-free interaction analysis of biomolecules
More informationSmall-Molecule Kinetics
Application Note No. 1 / February 4, 2015 Small-Molecule Kinetics Creoptix WAVE Small-Molecule Kinetics: Binding of Sulfonamides to Carbonic Anhydrase II Summary Label-free interaction analysis of biomolecules
More informationIsothermal Titration Calorimetry in Drug Discovery. Geoff Holdgate Structure & Biophysics, Discovery Sciences, AstraZeneca October 2017
Isothermal Titration Calorimetry in Drug Discovery Geoff Holdgate Structure & Biophysics, Discovery Sciences, AstraZeneca October 217 Introduction Introduction to ITC Strengths / weaknesses & what is required
More informationDepartment of Biochemistry, University of Zürich, Winterthurerstrasse 190, CH-8057 Zürich, Switzerland
Supporting information Twenty crystal structures of bromodomain and PHD finger containing protein 1 (BRPF1)/ligand complexes reveal conserved binding motifs and rare interactions Jian Zhu and Amedeo Caflisch*
More informationLa RMN quantitative appliquée aux petites molécules
La RMN quantitative appliquée aux petites molécules Fabrice Moriaud - Applications Development - Fällanden 30ème Réunion d Utilisateurs RMN Bruker December 9, 2016 1 Covered in this presentation Quantification
More informationHit Finding and Optimization Using BLAZE & FORGE
Hit Finding and Optimization Using BLAZE & FORGE Kevin Cusack,* Maria Argiriadi, Eric Breinlinger, Jeremy Edmunds, Michael Hoemann, Michael Friedman, Sami Osman, Raymond Huntley, Thomas Vargo AbbVie, Immunology
More informationThe Nanostream (Pasadena, CA) Veloce system,
Micro Parallel Liquid Chromatography for High- Throughput Compound Purity Analysis and Early ADMET Profiling Paren Patel,* Sergey Osechinskiy, Jeff Koehler, Li Zhang, Surekha Vajjhala, Chris Philips, and
More informationKinetic & Affinity Analysis
Kinetic & Affinity Analysis An introduction What are kinetics and affinity? Kinetics How fast do things happen? Time-dependent Association how fast molecules bind Dissociation how fast complexes fall apart
More informationApplication Note. Authors. Introduction. Lauren E. Frick and William A. LaMarr Agilent Technologies, Inc. Wakefield, MA, USA
Fragment-Based Drug Discovery: Comparing Labeled and Label-Free Screening of β-amyloid Secretase (BACE-1) Using Fluorescence Spectroscopy and Ultrafast SPE/MS/MS Application Note Authors Lauren E. Frick
More informationNanoliter Scale High-Throughput Protein Crystallography Screening with the Echo Liquid Handler
TM Application Note P100 Echo Liquid Handler Nanoliter Scale High-Throughput Protein Crystallography Screening with the Echo Liquid Handler Bonnie Edwards, David Harris Labcyte Inc. Abstract The Echo liquid
More informationComputational chemical biology to address non-traditional drug targets. John Karanicolas
Computational chemical biology to address non-traditional drug targets John Karanicolas Our computational toolbox Structure-based approaches Ligand-based approaches Detailed MD simulations 2D fingerprints
More informationProduct Bulletin. ACE LC/MS and Rapid Analysis HPLC Columns. HPLC Columns
Product Bulletin HPLC Columns ACE LC/MS and Rapid Analysis HPLC Columns 0 mm, 30 mm, 35 mm and 50 mm column lengths.0,., 3.0, 4.0 and 4.6 mm column diameters Configured for High Sample Throughput Specially
More information+ butanal + 2-picolineborane. + acetic acid. + butanal + 2-picolineborane. + acetic acid
PO-CON1751E Quantitation of plasma metanephrine and normetanephrine by derivatization using an integrated LC-MS/MS analyzer equipped with fully-automated sample preparation device ASMS 2017 ThP-099 Atsuhiko
More informationDr. Sander B. Nabuurs. Computational Drug Discovery group Center for Molecular and Biomolecular Informatics Radboud University Medical Centre
Dr. Sander B. Nabuurs Computational Drug Discovery group Center for Molecular and Biomolecular Informatics Radboud University Medical Centre The road to new drugs. How to find new hits? High Throughput
More informationCHIRAL SEPARATION USING THIN LAYER CHROMATOGRAPHY
CHIRAL SEPARATION USING THIN LAYER CHROMATOGRAPHY Chiral Chromatography Chiral - adjective: not superimposable on its mirror image: used to describe a molecule whose arrangement of atoms is such that it
More informationQuality control analytical methods- Switch from HPLC to UPLC
Quality control analytical methods- Switch from HPLC to UPLC Dr. Y. Padmavathi M.pharm,Ph.D. Outline of Talk Analytical techniques in QC Introduction to HPLC UPLC - Principles - Advantages of UPLC - Considerations
More informationSupporting Information
Supporting Information Synthesis of a new class of ribose functionalized dinucleotide cap analogues for biophysical studies on interaction of cap-binding proteins with the 5 end of mrna. Karolina Piecyk,
More informationQuantification of free ligand conformational preferences by NMR and their relationship to the bioactive conformation
Quantification of free ligand conformational preferences by NMR and their relationship to the bioactive conformation Charles Blundell charles.blundell@c4xdiscovery.com www.c4xdiscovery.com Rigid: single
More informationRoadblocks in HTS Assay Development
Roadblocks in HTS Assay Development Average HTS biochemical assay development time = 4.1 months One off assay development is typically required for each enzyme class Novel or complex targets can be difficult
More informationVirtual Screening: How Are We Doing?
Virtual Screening: How Are We Doing? Mark E. Snow, James Dunbar, Lakshmi Narasimhan, Jack A. Bikker, Dan Ortwine, Christopher Whitehead, Yiannis Kaznessis, Dave Moreland, Christine Humblet Pfizer Global
More informationSupporting Information for: Using a Lipase as a High Throughput Screening Method for Measuring the Enantiomeric. Excess of Allylic Acetates
Supporting Information for: Using a Lipase as a High Throughput Screening Method for Measuring the Enantiomeric Excess of Allylic Acetates M. Burak Onaran and Christopher T. Seto* Department of Chemistry,
More informationPeptide Isolation Using the Prep 150 LC System
Jo-Ann M. Jablonski and Andrew J. Aubin Waters Corporation, Milford, MA, USA APPLICATION BENEFITS The Prep 150 LC System, an affordable, highly reliable system for preparative chromatography, is suitable
More informationCOMBINATORIAL CHEMISTRY IN A HISTORICAL PERSPECTIVE
NUE FEATURE T R A N S F O R M I N G C H A L L E N G E S I N T O M E D I C I N E Nuevolution Feature no. 1 October 2015 Technical Information COMBINATORIAL CHEMISTRY IN A HISTORICAL PERSPECTIVE A PROMISING
More informationSix Biophysical Screening Methods Miss a Large Proportion of Crystallographically Discovered Fragment Hits: A Case Study
Six Biophysical Screening Methods Miss a Large Proportion of Crystallographically Discovered Fragment Hits: A Case Study Johannes Schiebel 1, Nedyalka Radeva 1, Stefan G. Krimmer 1, Xiaojie Wang 1, Martin
More informationCharacterization of Reversible Kinase Inhibitors using Microfluidic Mobility-Shift Assays
Application Note 211 Characterization of Reversible Kinase Inhibitors using Microfluidic Mobility-Shift Assays Introduction Current drug discovery efforts typically focus on developing small molecule inhibitors
More informationSupporting Information. for
Supporting Information for Near-Infrared Fluorescent Turn-On Probe with a Remarkable Large Stokes Shift for Imaging Selenocysteine in Living Cells and Animals Weiyong Feng, Meixing Li, Yao Sun, and Guoqiang
More informationTag lite: assessment of compound dissociation from GPCRs. Israel Ramos Villullas Group leader of GPCRs and Ion Channels unit BRADS Department
Tag lite: assessment of compound dissociation from GPCRs Israel Ramos Villullas Group leader of GPCRs and Ion Channels unit BRADS Department 1 INTRODUCTION Compound residence time at protein targets is
More informationLanthaScreen Eu Kinase Binding Assay Validation Packet. Optimization of a LanthaScreen Eu Kinase Binding Assay for AURKB
Page 1 of 18 LanthaScreen Eu Kinase Binding Assay for AURKB Overview This protocol describes how to perform a LanthaScreen Eu Kinase Binding Assay designed to detect and characterize kinase inhibitors.
More informationConfirmation of In Vitro Nefazodone Metabolites using the Superior Fragmentation of the QTRAP 5500 LC/MS/MS System
Confirmation of In Vitro Nefazodone Metabolites using the Superior Fragmentation of the QTRAP 5500 LC/MS/MS System Claire Bramwell-German, Elliott Jones and Daniel Lebre AB SCIEX, Foster City, California
More information(Supplementary Information)
(Supplementary Information) Peptidomimetic-based Multi-Domain Targeting Offers Critical Evaluation of Aβ Structure and Toxic Function Sunil Kumar 1*, Anja Henning-Knechtel 2, Mazin Magzoub 2, and Andrew
More informationLanthaScreen Eu Kinase Binding Assay Validation Packet. Optimization of a LanthaScreen Eu Kinase Binding Assay for RPS6KA1
Page 1 of 18 Optimization of a Assay for RPS6KA1 Assay for RPS6KA1 Overview This protocol describes how to perform a Assay designed to detect and characterize kinase inhibitors. Procedure 1 describes an
More informationSupporting Information. Labeled Ligand Displacement: Extending NMR-based Screening of Protein Targets
Supporting Information Labeled Ligand Displacement: Extending NMR-based Screening of Protein Targets Steven L. Swann, Danying Song, Chaohong Sun, Philip J. Hajduk, and Andrew M. Petros Global Pharmaceutical
More informationElectronic Supplementary Information for. A Redox-Nucleophilic Dual-Reactable Probe for Highly Selective
Electronic Supplementary Information for A Redox-Nucleophilic Dual-Reactable Probe for Highly Selective and Sensitive Detection of H 2 S: Synthesis, Spectra and Bioimaging Changyu Zhang, 1 Runyu Wang,
More informationBiophysics Service at the MPIB Biochemistry Core Facility Stephan Uebel, Biochemistry Core Facility
Biophysics Service at the MPIB Biochemistry Core Facility 30.11.2015 Stephan Uebel, Biochemistry Core Facility uebel@biochem.mpg.de Overview Peptide Chemistry - Peptide synthesis -Amino acid analysis -
More information17. Biomolecular Interaction
17. Biomolecular Interaction Methods for characterizing biomolecular interactions Sequence-specific DNA binding ligands Molecular mechanisms of drug action and drug resistance In silico compound design
More informationLanthaScreen Eu Kinase Binding Assay Validation Packet
Page of 7 LanthaScreen Eu kinase binding assay for RF Overview This protocol describes how to perform a LanthaScreen Eu Kinase indng ssay designed to detect and characterize kinase inhibitors. Procedure
More informationImprovIng ADmE ScrEEnIng productivity In Drug DIScovEry
Improving ADME Screening Productivity in Drug Discovery INTRODUCTION Improving the quality of the decisions made at the drug discovery stage can profoundly impact the efficiency of the drug discovery and
More informationPresentation Microcalorimetry for Life Science Research
Presentation Microcalorimetry for Life Science Research MicroCalorimetry The Universal Detector Heat is either generated or absorbed in every chemical process Capable of thermal measurements over a wide
More informationNMR study of complexes between low molecular mass inhibitors and the West Nile virus NS2B-NS3 protease
University of Wollongong Research Online Faculty of Science - Papers (Archive) Faculty of Science, Medicine and Health 2009 NMR study of complexes between low molecular mass inhibitors and the West Nile
More informationLC Technical Information
LC Technical Information Method Transfer to Accucore.6 μm Columns Containing solid core particles, which are engineered to a diameter of.6μm and a very narrow particle size distribution; Accucore HPLC
More informationThis is a repository copy of Biophysics in drug discovery : impact, challenges and opportunities.
This is a repository copy of Biophysics in drug discovery : impact, challenges and opportunities. White Rose Research Online URL for this paper: http://eprints.whiterose.ac.uk/105185/ Version: Accepted
More informationAccelerating the Metabolite Identification Process Using High Resolution Q-TOF Data and Mass-MetaSite Software
Accelerating the Metabolite Identification Process Using High Resolution Q-TOF Data and Mass-MetaSite Software Application ote Drug discovery and development: Metabolite Identifi cation Authors Yuqin Dai,
More informationProblem Set 5 Question 1
2.32 Problem Set 5 Question As discussed in class, drug discovery often involves screening large libraries of small molecules to identify those that have favorable interactions with a certain druggable
More informationFRAUNHOFER IME SCREENINGPORT
FRAUNHOFER IME SCREENINGPORT Design of screening projects General remarks Introduction Screening is done to identify new chemical substances against molecular mechanisms of a disease It is a question of
More informationBRIEFING. (EXC: K. Moore.) RTS C Propylparaben C 10 H 12 O Benzoic acid, 4 hydroxy, propyl ester; Propyl p hydroxybenzoate [ ].
BRIEFING Propylparaben. The European Pharmacopoeia is the coordinating pharmacopeia for the international harmonization of the compendial standards for the Propylparaben monograph, as part of the process
More informationUltra-HTS Using 3456-Well Plate and HTRF Technology in GPCR Drug Discovery
Ultra-HTS Using 3456-Well Plate and HTRF Technology in GPCR Drug Discovery 29 th Sep 2016 Toyo Sakurai Hit Discovery and Cell Processing Research Group, Biological Research Department Agenda 3456-well
More informationImproved 6- Plex TMT Quantification Throughput Using a Linear Ion Trap HCD MS 3 Scan Jane M. Liu, 1,2 * Michael J. Sweredoski, 2 Sonja Hess 2 *
Improved 6- Plex TMT Quantification Throughput Using a Linear Ion Trap HCD MS 3 Scan Jane M. Liu, 1,2 * Michael J. Sweredoski, 2 Sonja Hess 2 * 1 Department of Chemistry, Pomona College, Claremont, California
More informationImportant Aspects of Fragment Screening Collection Design
Important Aspects of Fragment Screening Collection Design Phil Cox, Ph. D., Discovery Chemistry and Technology, AbbVie, USA Cresset User Group Meeting, Cambridge UK. Thursday, June 29 th 2017 Disclosure-
More informationUsing AutoDock for Virtual Screening
Using AutoDock for Virtual Screening CUHK Croucher ASI Workshop 2011 Stefano Forli, PhD Prof. Arthur J. Olson, Ph.D Molecular Graphics Lab Screening and Virtual Screening The ultimate tool for identifying
More informationCHAPTER 1 Role of Bioanalytical Methods in Drug Discovery and Development
UMMERY The need to develop new analytical methods for assurance of quality, safety and efficacy of drugs and pharmaceuticals is quite important because of their use not only as health care products but
More informationRapid and Accurate Forensics Analysis using High Resolution All Ions MS/MS
Rapid and Accurate Forensics Analysis using High Resolution All Ions MS/MS Application Note Forensic Toxicology Authors Martin Josefsson, and Markus Roman National Board of Forensic Medicine Linköping,
More informationSUPPLEMENTARY INFORMATION
Synthetic chemistry ML5 and ML4 were identified as K P.(TREK-) activators using a combination of fluorescence-based thallium flux and automated patch-clamp assays. ML5, ML4, and ML5a were synthesized using
More informationMnova Software Tools for Fragment-Based Drug Discovery
Mnova Software Tools for Fragment-Based Drug Discovery Chen Peng, PhD, VP of Business Development, US & China Mestrelab Research SL San Diego, CA chen.peng@mestrelab.com 858.736.4563 Agenda Brief intro
More informationApplications of Fragment Based Approaches
Applications of Fragment Based Approaches Ben Davis Vernalis R&D, Cambridge UK b.davis@vernalis.com 1 Applications of Fragment Based Approaches creening fragment libraries Techniques Vernalis eeds approach
More informationTEMPLATE FOR AN EXAMPLE STANDARD TEST METHOD
APPENDIX V TEMPLATE FOR AN EXAMPLE STANDARD TEST METHOD Validating Chromatographic Methods. By David M. Bliesner Copyright 2006 John Wiley & Sons, Inc. 159 160 APPENDIX V Title: Effective: Document No:
More informationChapter 6. The interaction of Src SH2 with the focal adhesion kinase catalytic domain studied by NMR
The interaction of Src SH2 with the focal adhesion kinase catalytic domain studied by NMR 103 Abstract The interaction of the Src SH2 domain with the catalytic domain of FAK, including the Y397 SH2 domain
More informationProtein structure based approaches to inhibit Plasmodium DHODH for malaria
Protein structure based approaches to inhibit Plasmodium DHDH for malaria Peter Johnson University of Leeds, School of Chemistry email p.johnson@leeds.ac.uk Tools for protein structure based approaches
More informationHigh Performance Liquid Chromatography. Table 1: Allowed HPLC Adjustment of USP <621> and EP <2.2.46>
High Performance Liquid Chromatography HPLC-9 Ultra-high Speed Analysis of Ibuprofen within USP Allowed Limits by Nexera Method Scouting In recent years, high-throughput analytical techniques have
More informationQuantitation of a target protein in crude samples using targeted peptide quantification by Mass Spectrometry
Quantitation of a target protein in crude samples using targeted peptide quantification by Mass Spectrometry Jon Hao, Rong Ye, and Mason Tao Poochon Scientific, Frederick, Maryland 21701 Abstract Background:
More informationDispensing Processes Profoundly Impact Biological, Computational and Statistical Analyses
Dispensing Processes Profoundly Impact Biological, Computational and Statistical Analyses Sean Ekins 1, Joe Olechno 2 Antony J. Williams 3 1 Collaborations in Chemistry, Fuquay Varina, NC. 2 Labcyte Inc,
More informationShodex TM ODP2 HP series columns
HPLC Columns Shodex TM ODP2 HP series columns Better retention of highly polar substances Technical notebook No. 6 Contents 1. Introduction 1-1. Specifications 1-2. Eluent Compatibility of ODP2 HP Series
More informationPhoto-responsive MOFs: Light-induced switching of porous single crystals containing photochromic diarylethene
Supplementary information Photo-responsive MOFs: Light-induced switching of porous single crystals containing photochromic diarylethene Ian M. Walton, a Jordan Cox, a Jarrett Coppin, a Crysania Linderman,
More informationHIGH-THROUGHPUT DETERMINATION OF AQUEOUS SOLUBILITY, PRECIPITATION OR COLLOIDAL AGGREGATE FORMATION IN SMALL MOLECULE SCREENING SETS
HIGH-THROUGHPUT DETERMINATION OF AQUEOUS SOLUBILITY, PRECIPITATION OR COLLOIDAL AGGREGATE FORMATION IN SMALL MOLECULE SCREENING SETS Introduction: Determining the aqueous solubility of a compound is an
More informationSupporting Information
Protein-Observed Fluorine NMR is a Complementary Ligand Discovery Method to 1 H CPMG Ligand- Observed NMR. Andrew K. Urick, 1,2 Luis Pablo Calle, 3 Juan F. Espinosa, 3 Haitao Hu, 2 * William C. K. Pomerantz
More informationElectronic Supplementary Information for: agent. Adam J. Plaunt, Kasey J. Clear, and Bradley D. Smith*
Electronic Supplementary Material (ESI) for ChemComm. This journal is The Royal Society of Chemistry 2014 Electronic Supplementary Information for: 19 F NMR indicator displacement assay using synthetic
More informationAdvanced Medicinal Chemistry SLIDES B
Advanced Medicinal Chemistry Filippo Minutolo CFU 3 (21 hours) SLIDES B Drug likeness - ADME two contradictory physico-chemical parameters to balance: 1) aqueous solubility 2) lipid membrane permeability
More informationHPLC AND 13 C NMR FOR ANALYSIS OF TRANSAMIDATION IN A DYNAMIC COMBINATORIAL CHEMISTRY SYSTEM
ACTA CHROMATOGRAPHICA, O. 17, 26 HPLC AD 13 C MR FOR AALYSIS OF TRASAMIDATIO I A DYAMIC COMBIATORIAL CHEMISTRY SYSTEM A. Pałka, R. Musioł, H. iedbała, M. Matlengiewicz, M. Sajewicz, K. Serafin, and J.
More information(Supplementary Information)
Foldamer-mediated Structural Rearrangement Attenuates Aβ Oligomerization and Cytotoxicity (Supplementary Information) Sunil Kumar* 1, Anja Henning-Knechtel 2, Ibrahim Chehade 2, Mazin Magzoub 2, and Andrew
More informationIn silico pharmacology for drug discovery
In silico pharmacology for drug discovery In silico drug design In silico methods can contribute to drug targets identification through application of bionformatics tools. Currently, the application of
More informationUse of Ultra-High Performance LC-MS for Challenging Assays. David Browne, Laboratory Manager (LC-MS-MS), Covance Laboratories, Harrogate
Use of Ultra-High Performance LC-MS for Challenging Assays David Browne, Laboratory Manager (LC-MS-MS), Covance Laboratories, Harrogate Department of Bioanalytical Services Determination of drug substance
More informationA High Sensitivity Dual Solid Phase Extraction LC-MS/MS Assay for the Determination of the Therapeutic Peptide Desmopressin in Human Plasma
White Paper A High Sensitivity Dual Solid Phase Extraction LC-MS/MS Assay for the Determination of the Therapeutic Peptide Desmopressin in Human Plasma Lars Neudert, MSc, Senior Scientist Method Development
More informationMaximizing Triple Quadrupole Mass Spectrometry Productivity with the Agilent StreamSelect LC/MS System
Maximizing Triple Quadrupole Mass Spectrometry Productivity with the Agilent StreamSelect LC/MS System Application Note Authors Kevin McCann, Sameer Nene, Doug McIntyre, Edmond Neo, Dennis Nagtalon, and
More informationSupporting Information
Supporting Information Discovery and optimization of a selective ligand for the Switch/Sucrose Non-Fermenting-related bromodomains of Polybromo protein-1 by the use of virtual screening and hydration analysis.
More informationStructure-based maximal affinity model predicts small-molecule druggability
Structure-based maximal affinity model predicts small-molecule druggability Alan Cheng alan.cheng@amgen.com IMA Workshop (Jan 17, 2008) Druggability prediction Introduction Affinity model Some results
More informationCOMBINATORIAL CHEMISTRY: CURRENT APPROACH
COMBINATORIAL CHEMISTRY: CURRENT APPROACH Dwivedi A. 1, Sitoke A. 2, Joshi V. 3, Akhtar A.K. 4* and Chaturvedi M. 1, NRI Institute of Pharmaceutical Sciences, Bhopal, M.P.-India 2, SRM College of Pharmacy,
More informationZAHID IQBAL WARRAICH
Q1 Chromatography is an important analytical technique in chemistry. There is a number of techniques under the general heading of chromatography. (a) Paper and gas chromatography rely on partition to separate
More informationMolecular Imaging of Labile Iron(II) Pools in Living Cells with a Turn-on Fluorescent Probe
Supporting Information for Molecular Imaging of Labile Iron(II) Pools in Living Cells with a Turn-on Fluorescent Probe Ho Yu Au-Yeung, Jefferson Chan, Teera Chantarojsiri and Christopher J. Chang* Departments
More informationMulti-residue analysis of pesticides by GC-HRMS
An Executive Summary Multi-residue analysis of pesticides by GC-HRMS Dr. Hans Mol is senior scientist at RIKILT- Wageningen UR Introduction Regulatory authorities throughout the world set and enforce strict
More informationSupplementary Table 1. Small molecule screening data
Supplementary Table 1. Small molecule screening data Category Parameter Description Assay Type of assay Cell-based Target Primary measurement Key reagents Assay protocol PS1/BACE1 interaction Detection
More informationIntelligent NMR productivity tools
Intelligent NMR productivity tools Till Kühn VP Applications Development Pittsburgh April 2016 Innovation with Integrity A week in the life of Brian Brian Works in a hypothetical pharma company / university
More information3) In CE separation is based on what two properties of the solutes? (3 pts)
Final Exam Chem 311 Fall 2002 December 16 Name 1) (3 pts) In GC separation is based on the following two properties of the solutes a) polarity and size b) vapor pressure and molecular weight c) vapor pressure
More informationRational design of a hexapeptide hydrogelator for controlled-release drug delivery
Electronic Supplementary Material (ESI) for Journal of Materials Chemistry B. This journal is The Royal Society of Chemistry 2014 Supporting Information for Rational design of a hexapeptide hydrogelator
More informationApplication Note. Edgar Naegele. Abstract
Fast identification of main drug metabolites by quadrupole time-of-flight LC/MS Measuring accurate MS and MS/MS data with the Agilent 651 Q-TOF LC/MS and identification of main meta-bolites by comparison
More informationHighly automated protein formulation development: a case study
Application Note Highly automated protein formulation development: a case study Introduction and background Therapeutic proteins can be inherently prone to degradation and instability, and they often pose
More informationRevision Bulletin 27 Jan Feb 2017 Non-Botanical Dietary Supplements Compliance
Niacin Extended-Release Tablets Type of Posting Posting Date Official Date Expert Committee Reason for Revision Revision Bulletin 27 Jan 2017 01 Feb 2017 Non-Botanical Dietary Supplements Compliance In
More informationReceptor Based Drug Design (1)
Induced Fit Model For more than 100 years, the behaviour of enzymes had been explained by the "lock-and-key" mechanism developed by pioneering German chemist Emil Fischer. Fischer thought that the chemicals
More informationEMPIRICAL VS. RATIONAL METHODS OF DISCOVERING NEW DRUGS
EMPIRICAL VS. RATIONAL METHODS OF DISCOVERING NEW DRUGS PETER GUND Pharmacopeia Inc., CN 5350 Princeton, NJ 08543, USA pgund@pharmacop.com Empirical and theoretical approaches to drug discovery have often
More informationMacrolides in Honey Using Agilent Bond Elut Plexa SPE, Poroshell 120, and LC/MS/MS
Macrolides in Honey Using Agilent Bond Elut Plexa SPE, Poroshell 120, and LC/MS/MS Application Note Food Testing and Agriculture Author Chen-Hao (Andy) Zhai and Rong-jie Fu Agilent Technologies (Shanghai)
More informationSupporting Information
S-1 Supporting Information Flaviviral protease inhibitors identied by fragment-based library docking into a structure generated by molecular dynamics Dariusz Ekonomiuk a, Xun-Cheng Su b, Kiyoshi Ozawa
More information